Tiziana Life Sciences is a biotechnology firm that specializes in developing drugs to cure human diseases in oncology and immunology. The company's lead product candidate, Foralumab, is a human anti-CD3 monoclonal antibody used to treat several diseases, including Crohn's and multiple sclerosis. Tiziana also produces Milciclib and TZLS-501, used to control cell growth and treat COVID-19 patients, respectively.